EN
EN
CN
JP
KR
HOME
MOUSE MODELS
MOUSE MODELS
Knockout & Conditional Knockout Mouse Models
Disease Mouse Models
Germ-Free Mouse Models
Tool Mice
Immunodeficient Mouse Models
The Wild Mouse Project
NeoMab™ Antibody Fully-Humanized Mouse Models
SERVICES
SERVICES
Custom Model Generation Services
Preclinical Testing Services
Germ-Free and Microbiome Services
Cell Lines and Customization Services
Custom Breeding Services
Animal Quality Testing Services
Assay Capabilities
NeoMab™ Fully-Human Antibody Dicovery
Other Services
NEWS & RESOURCES
NEWS & RESOURCES
News
Events
Webinars
Resources
Blogs
ABOUT US
ABOUT US
GemPharmatech USA
GemPharmatech Headquarters
Facilities
Careers
Contact Us
Quality Management System
Advanced Search
Hot Search:
NCG
Wild Mice
CD3
BAFF
FAD
NCG-X
NCG-hIL15
Research Field:
Immune System
Developmental Biology
Nervous System
Oncolgoy Research
Tool Mice
Humanized Mouse Model
Disease and Drug Evaluation Model
Other Models
Research Field:
Gene humanization model
Tissue humanization model
Humanized flora model
NOD/ShiLtJGpt-
Prkdc
em26Cd52
Il2rg
em26Cd22
/Gpt
NCG|Strain NO.T001475
Knockout (KO)
Product Type:
Live Mouse
Sperm
Frozen Embryo
Quantity:
-
+
Sex:
Male
Female
Age:
1 weeks
2 weeks
3 weeks
4 weeks
5 weeks
6 weeks
7 weeks
8 weeks
9 weeks
10 weeks
11 weeks
12 weeks
13 weeks
14 weeks
15 weeks
16 weeks
17 weeks
18 weeks
19 weeks
20 weeks
21 weeks
22 weeks
23 weeks
24 weeks
25 weeks
26 weeks
27 weeks
28 weeks
29 weeks
30 weeks
>30 weeks
Genotype:
(Prkdc)KO/KO,(Il2rg)ko/Y
(Prkdc)KO/KO,(Il2rg)KO/KO
Add to cart
BASIC INFORMATION
Strain Name:
NOD/ShiLtJGpt-
Prkdc
em26Cd52
Il2rg
em26Cd22
/Gpt
Strain Number:
T001475
Official Symbol:
Prkdc,Il2rg
Strain Strategy:
T001475.NCG strain info.pdf
Official Full Name:
protein kinase DNA activated catalytic polypeptide,interleukin 2 receptor gamma chain
Also Known As:
AI326420,AU019811,DNA-PKcs,DNAPDcs,DNAPK,DNPK1,DOXNPH,HYRC1,XRCC7,dxnph,p460
NCBI Number:
19090
16186
MGI Number:
104779
96551
Research Areas:
Humanized model,Humanization of the immune system,Immunodeficiency
Strain Background:
[N000235] NOD/ShiLtJGpt
Modification Type:
Knockout (KO)
Inventory Status:
Live,Cryopreserved
Sale Status:
IF (Available for Distribution)
Health Status:
Specific pathogen free (SPF)
Health Report:
Please log in to view
Publications:
1. Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment
2. Cytoplasmic NEAT1 Suppresses AML Stem Cell Self‐Renewal and Leukemogenesis through Inactivation of Wnt Signaling
3. Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML
4. Biomimetic Nanoerythrosome‐Coated Aptamer‐DNA Tetrahedron/Maytansine Conjugates: pH‐Responsive and Targeted Cytotoxicity for HER2‐positive Breast Cancer
5. Interferon-a potentiates anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment
6. Autologous transplantation of thecal stem cells restores ovarian function in nonhuman primates
7. ACSS3 represses prostate cancer progression through downregulating lipid droplet-associated protein PLIN3
8. Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1
9. Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling
10. Creatine promotes cancer metastasis through activation of Smad2/3
11. Rapamycin pretreatment rescues the bone marrow AML cell elimination capacity of CAR-T cells
12. AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia
13. Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors
14. Development of an antibody-like T-cell engager based on VH-VL heterodimer formation and its application in cancer therapy
15. The Rational Development of CD5-targeting Biepitopic Chimeric Antigen Receptors with Fully Human Heavy-chain-only Antigen Recognition Domains
16. N7-Methylguanosine tRNA modification enhances oncogenic mRNA translation and promotes intrahepatic cholangiocarcinoma progression
17. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors
18. ARID1A hypermethylation disrupts transcriptional homeostasis to promote squamous cell carcinoma progression
19. ARID1A prevents squamous cell carcinoma initiation and chemoresistance by antagonizing pRb/E2F1/c-Myc-mediated cancer stemness
20. Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy
21. Dendrimer-Functionalized Superparamagnetic Nanobeacons for Real-Time Detection and Depletion of HSP90α mRNA and MR Imaging
22. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study
23. OXTR(High) stroma fibroblasts control the invasion pattern of oral squamous cell carcinoma via ERK5 signaling
24. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL
25. Acquired semi-squamatization during chemotherapy suggests differentiation as a therapeutic strategy for bladder cancer
26. Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma
27. Identification of novel HLA-A*11:01-restricted HPV16 E6/E7 epitopes and T-cell receptors for HPV-related cancer immunotherapy
28. Targeting ARF1-IQGAP1 interaction to suppress colorectal cancer metastasis and vemurafenib resistance
29. Hook&Loop multivalent interactions based on disk-shaped nanoparticles strengthen active targeting
30. Downregulation of phosphoserine phosphatase potentiates tumor immune environments to enhance immune checkpoint blockade therapy
31. BPA‐Containing Polydopamine Nanoparticles for Boron Neutron Capture Therapy in a U87 Glioma Orthotopic Model
32. Anti-BCMA surface engineered biomimetic photothermal nanomissile enhances multiple myeloma cell apoptosis and overcomes the disturbance of NF-kappaB signaling in vivo
33. EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1
34. Expansion of human megakaryocyte-biased hematopoietic stem cells by biomimetic Microniche
35. Supramolecular nanofibers co-loaded with dabrafenib and doxorubicin for targeted and synergistic therapy of differentiated thyroid carcinoma
36. PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
37. Impaired histone inheritance promotes tumor progression
38. NOTCH4(DeltaL12_16) sensitizes lung adenocarcinomas to EGFR-TKIs through transcriptional down-regulation of HES1
39. Targeting Trop2 by Bruceine D suppresses breast cancer metastasis by blocking Trop2/beta-catenin positive feedback loop
40. GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer
41. Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFRbeta complex in hepatocellular carcinoma
42. Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment
43. Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models
44. Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma
45. Targeting Bcl-xL is a potential therapeutic strategy for extranodal NK/T cell lymphoma
46. Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin
47. WDR54 exerts oncogenic roles in T-cell acute lymphoblastic leukemia
48. Activation of melanocortin-1 receptor signaling in melanoma cells impairs T cell infiltration to dampen antitumor immunity
49. Downregulation of RCN1 promotes pyroptosis in acute myeloid leukemia cells
50. The application of HER2 and CD47 CAR-macrophage in ovarian cancer
51. A drug-delivery depot for epigenetic modulation and enhanced cancer immunotherapy
52. A human mucosal melanoma organoid platform for modeling tumor heterogeneity and exploring immunotherapy combination options
53. Intratumoral CD103(+) CD8(+) T cells predict response to neoadjuvant chemoimmunotherapy in advanced head and neck squamous cell carcinoma
54. Novel mesothelin-targeted chimeric antigen receptor-modified UNKT cells are highly effective in inhibiting tumor progression
55. The liver microenvironment orchestrates FGL1-mediated immune escape and progression of metastatic colorectal cancer
56. Enhancement of the viability of T cells electroporated with DNA via osmotic dampening of the DNA-sensing cGAS-STING pathway
57. Lipid accumulation-mediated histone hypoacetylation drives persistent NK cell dysfunction in anti-tumor immunity
58. Cell surface GRP78-directed CAR-T cells are effective at treating human pancreatic cancer in preclinical models
59. GARP-mediated active TGF-beta1 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT
60. Long noncoding RNA NONHSAT160169.1 promotes resistance via hsa-let-7c-3p/SOX2 axis in gastric cancer
61. Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51
62. Tumor-infiltrating platelets promote the growth of lung adenocarcinoma
63. Carboxypeptidase A4 negatively regulates HGS-ETR1/2-induced pyroptosis by forming a positive feedback loop with the AKT signalling pathway
64. Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical application
65. Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma
66. Hepatitis B Virus-Encoded MicroRNA (HBV-miR-3) Inhibits FIH-1 Expression to Promote Tumor Angiogenesis in HBV-Related Hepatocellular Carcinoma
67. A Near-Infrared-II Fluorescent Nanocatalyst for Enhanced CAR T Cell Therapy against Solid Tumor by Immune Reprogramming
68. Sufficiently activated mature natural killer cells derived from peripheral blood mononuclear cells substantially enhance antitumor activity
69. IL-21-armored B7H3 CAR-iNKT cells exert potent antitumor effects
70. FKBP10 promotes clear cell renal cell carcinoma progression and regulates sensitivity to the HIF2alpha blockade by facilitating LDHA phosphorylation
71. Enhanced Precision Therapy of Multiple Myeloma Through Engineered Biomimetic Nanoparticles with Dual Targeting
72. Cell-Surface GRP78-Targeted Chimeric Antigen Receptor T Cells Eliminate Lung Cancer Tumor Xenografts
73. An Anti-CD7 Antibody-Drug Conjugate Target Showing Potent Antitumor Activity for T-Lymphoblastic Leukemia (T-ALL)
74. Effects of methionine deficiency on B7H3-DAP12-CAR-T cells in the treatment of lung squamous cell carcinoma
75. Endoplasmic reticulum aminopeptidase 2 regulates CD4(+) T cells pyroptosis in rheumatoid arthritis
76. RNA-binding protein RBM5 plays an essential role in acute myeloid leukemia by activating the oncogenic protein HOXA9
77. A trispecific antibody induces potent tumor-directed T-cell activation and antitumor activity by CD3/CD28 co-engagement
78. MTHFD1 regulates the NADPH redox homeostasis in MYCN-amplified neuroblastoma
79. RORalpha is required for expansion and memory maintenance of ILC1s via a lymph node-liver axis
80. High-fat diet promotes prostate cancer metastasis via RPS27
81. CYP2E1-dependent upregulation of SIRT7 is response to alcohol mediated metastasis in hepatocellular carcinoma
82. The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments
83. RBP7 functions as a tumor suppressor in HR + breast cancer by inhibiting the AKT/SREBP1 pathway and reducing fatty acid
84. Inhibition of SFTSV replication in humanized mice by a subcutaneously administered anti-PD1 nanobody
85. Co-targeting CD47 and VEGF elicited potent anti-tumor effects in gastric cancer
86. Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
87. Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology
88. DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy
89. GATA3 functions downstream of BRCA1 to promote DNA damage repair and suppress dedifferentiation in breast cancer
90. ISG12a promotes immunotherapy of HBV-associated hepatocellular carcinoma through blocking TRIM21/AKT/beta-catenin/PD-L1 axis
91. m(6)A-dependent upregulation of DDX21 by super-enhancer-driven IGF2BP2 and IGF2BP3 facilitates progression of acute myeloid leukaemia
92. PTPLAD1 Regulates PHB-Raf Interaction to Orchestrate Epithelial-Mesenchymal and Mitofusion-Fission Transitions in Colorectal Cancer
93. PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion
94. Self-Assembled Multivalent Aptamer Drug Conjugates: Enhanced Targeting and Cytotoxicity for HER2-Positive Gastric Cancer
95. STING agonist diABZI enhances the cytotoxicity of T cell towards cancer cells
96. Cancer-associated fibroblasts derived fibronectin extra domain A promotes sorafenib resistance in hepatocellular carcinoma cells by activating SHMT1
97. CXCL10 and IL15 co-expressing chimeric antigen receptor T cells enhance anti-tumor effects in gastric cancer by increasing cytotoxic effector cell accumulation and survival
98. Elesclomol-copper synergizes with imidazole ketone erastin by promoting cuproptosis and ferroptosis in myelodysplastic syndromes
99. Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2
100. Expand available targets for CAR-T therapy to overcome tumor drug resistance based on the "Evolutionary Traps"
101. NCX1/Ca(2+) promotes autophagy and decreases bortezomib activity in multiple myeloma through non-canonical NFkappaB signaling pathway
102. Priming with LSD1 inhibitors promotes the persistence and antitumor effect of adoptively transferred T cells
103. Targeted degradation of oncogenic BCR-ABL by silencing the gene of NEDD8 E3 ligase RAPSYN
104. Zebularine potentiates anti-tumor immunity by inducing tumor immunogenicity and improving antigen processing through cGAS-STING pathway
0
Cart
Contact Us
Strain Manage